The Advanced Research Projects Agency for Health, an agency within the U.S. Department of Health and Human Services, announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program—a critical investment toward bringing new treatments to patients faster and curing rare genetic pediatric diseases.
The Trump administration has a fight on its hands as it pushes forward with a plan to exert greater political control over government funding of science.
